Masterson Richard Kevin 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Apr 16, 2012
Insider Transaction Report
Form 4
Masterson Richard Kevin
Pres.&COO, Valeant Int.(BB)SRL
Transactions
- Exercise/Conversion
Common Stock, no par values
2012-04-12+5,789→ 91,211 total - Tax Payment
Common Stock, no par values
2012-04-12−1,683→ 89,528 total - Exercise/Conversion
Restricted Share Units
2012-04-12−5,789→ 0 totalExercise: $0.00→ Common Stock, no par values (5,789 underlying)
Footnotes (4)
- [F1]Represents common shares withheld to satisfy certain tax obligations at the time of release.
- [F2]The RSUs accelerated vesting on the achievement of TSR hitting the 60% target, allowing for such acceleration.
- [F3]Each RSUs represents a contingent right to receive an equal number of common share, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (4).
- [F4]The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 15% to 45% over a base price on three separate measurement dates.